Canaccord analyst Tania Gonsalves lowered the firm’s price target on Antibe Therapeutics to C$0.50 from C$0.70 and keeps a Hold rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly